Analysis of safety of tirofiban for patients with acute progressive cerebral infarction
Objective To evaluate the practical value of tirofiban for patients with acute progressive cerebral infarction.Methods 317 patients with acute progressive cerebral infarction were divided into an observation group(167 cases)and a control group(150 cases)by random number table.The observation group was treated with tirofiban and conventional symptomatic treatment,and the control group was treated with conventional symptomatic treatment.The improvement of neurological function,life ability,platelet function and adverse reactions were compared between the two groups.Results After treatment,the National Institutes of Health Stroke Scale(NIHSS)score in both groups was lower than that before treatment,and the NIHSS score of(5.42±0.98)points in the observation group was lower than(7.24±1.16)points in the control group(P<0.05).After treatment,the Barthel index in both groups was higher than that before treatment,and Barthel index of(68.82±4.96)points in the observation group was higher than(60.83±4.21)points in the control group(P<0.05).After treatment,the observation group had platelet P-selectin of(10.61±1.25)%,platelet aggregation rate of(28.46±2.18)%and platelet adhesion rate of(34.44±3.22)%,which were lower than(13.02±1.84)%,(32.83±2.56)%and(37.80±3.80)%in the control group(P<0.05).The incidence of adverse reactions in the observation group was 7.78%(13/167),which was lower than 15.33%(23/150)in the control group(χ2=4.4732,P=0.0344<0.05).Conclusion The treatment of tirofiban in patients with acute progressive cerebral infarction has significant effect,and it is recommended for reference.
NETL
NSTL
万方数据
维普
